EMA Application withdrawn: Linhaliq — Aradigm Pharmaceuticals Limited

View source ↗

Summary

The EMA withdrew the application for Linhaliq by Aradigm Pharmaceuticals Limited for bronchiectasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis

Drugs mentioned

• Linhaliq

Snippet

Status: Application withdrawn. Therapeutic area: Bronchiectasis. MAH: Aradigm Pharmaceuticals Limited